Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
With
Astellas Pharma US, Inc.
A 3 arm study (2 Active, 1 Active Control) to determine the optimal dose and blood level of Prograf® in long-term maintenance of kidney transplant patients
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient was 18 years of age at the time of transplant.
Patient is at least 6 months post-transplant.
You may not be if
Patient is the recipient of a solid organ transplant other than the kidney.
Patient is a known carrier of any of the HIV viruses.
Clareo Health | Optimizing Prograf® Therapy in Renal Transplant Patients
